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Abstract The development of eVective anti-cancer vac-
cines requires precise assessment of vaccine-induced immu-
nity. This is often hampered by low ex vivo frequencies of
antigen-speciWc T cells and limited deWned epitopes. This
study investigates the applicability of modiWed, in vitro-tran-
scribed mRNA encoding a therapeutically relevant tumour
antigen to analyse T cell responses in cancer patients. In this
study transfection of antigen presenting cells, by mRNA
encoding the tumour antigen NY-ESO-1, was optimised and
applied to address spontaneous and vaccine-induced T cell
responses in cancer patients. Memory CD8+ T cells from
lung cancer patients having detectable humoral immune
responses directed towards NY-ESO-1 could be eYciently
detected in peripheral blood. SpeciWc T cells utilised a range
of diVerent T cell receptors, indicating a polyclonal response.
SpeciWc killing of a panel of NY-ESO-1 expressing tumour
cell lines indicates recognition restricted to several HLA
allelic variants, including a novel HLA-B49 epitope. Using a
modiWed mRNA construct targeting the translated antigen
to the secretory pathway, detection of NY-ESO-1-speciWc
CD4+ T cells in patients could be enhanced, which allowed
the in-depth characterisation of established T cell clones.
Moreover, broad CD8+ and CD4+ T cell responses covering
multiple epitopes were detected following mRNA stimula-
tion of patients treated with a recombinant vaccinia/fowlpox
NY-ESO-1 vaccine. This approach allows for a precise mon-
itoring of responses to tumour antigens in a setting that
addresses the breadth and magnitude of antigen-speciWc T
cell responses, and that is not limited to a particular combi-
nation of known epitopes and HLA-restrictions.
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Introduction
In the decade following the deWnition of the Wrst tumour anti-
gen [1] and the advancement of antigen discovery pro-
grammes, a growing number of therapeutic tumour targets
have been deWned. One of the most promising categories of
tumour-associated antigens (TAAs) are the cancer/testis (CT)
antigens, of which over 44 families of CT antigens have been
deWned [2]. CT antigens are ideal immunotherapeutical tar-
gets due to their highly restricted expression pattern and
broad immunogenicity [3]. A number of CT antigens have
been applied in phase I/II vaccine trials, and comprehensive
phase II/III trials employing CT antigens are underway or
planned [4]. Although it has been diYcult to deWnitively
associate induced immune responses with objective clinical
outcomes in the extensively employed peptide-based trials,
lessons learned from analysis of vaccine-induced immunity
have led to signiWcant advances in the Weld.
NY-ESO-1, a broadly expressed and highly immuno-
genic CT antigen, has been employed as a prototypal
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Recently, cancer patients were vaccinated with full length
NY-ESO-1 encoded by fowlpox virus or as a recombinant
protein, which resulted in the induction of a humoral
response and a broad oligoclonal cellular immune response
to multiple epitopes [7, 8]. Interestingly, a retrospective
observation of overall survival suggests that important clin-
ical responses may have been attained in those patients
receiving full-length protein and adjuvant, in comparison to
the placebo-controlled group (unpublished observation).
However, this observation, although promising, needs to be
conWrmed by an on-going phase II study with disease-free
survival as a primary endpoint.
In order to understand the mechanisms behind any
observed clinical eYcacy, it is critical to carefully dissect
the entire vaccine-induced immune response, i.e. the sum of
responses to all individual epitopes. For most tumour anti-
gens, however, only a limited number of epitopes and
restricting HLA alleles have been identiWed. The use of syn-
thetic overlapping peptides [8] or viral vectors encoding the
whole antigen [7] may overcome these hurdles. However,
the methods have inherent pitfalls that mRNA could over-
come. Issues with synthetic peptides include solubility,
aggregation and that natural post-translational modiWcations
of peptides are not represented within synthetic libraries,
where modiWed peptides may account for a large percentage
of MHC-associated peptides [9]. Moreover, long polypep-
tides such as those >12 amino acids require processing to
allow loading on MHC class I molecules, a process involv-
ing uptake and cross presentation. This is a major drawback
as cells that are often used as autologous antigen presenting
cell (APC), such as EBV-transformed B-lymphoblastoid
cell lines (B-LCL) or T-APC (CD4 T cell PHA blasts) are
unable to uptake and cross present soluble antigen and rely
on ineYcient exogenous loading by serum protease degra-
dation [10]. Another strategy employs transfection of autol-
ogous APC with gene constructs encoding the full length
antigen. However, viral delivery systems are generally more
diYcult to generate than peptides or puriWed nucleic acids,
many require restricted laboratory handling and, moreover,
are intrinsically antigenic themselves, thus potentially inXu-
encing the immunogenicity of the TAA they encode.
mRNA has been investigated as an antigen source for DC-
based therapy [11–13] and also directly as a vaccine agent
[14]. Recently several groups have investigated the applica-
tion of full-length antigen-encoding mRNA in the context
of in vitro analysis. However, many of these studies were
designed as proof of principle and investigated highly
immunogenic viral antigens such as inXuenza matrix pro-
tein [15] or CMV pp65 [16] where T cells are present in
high frequencies in many healthy donors.
In this study we describe the in vitro application of mod-
iWed mRNA encoding a therapeutically-relevant tumour
antigen to address anti-tumour immune responses in
patients. We were able to expand and detect NY-ESO-1
speciWc CD4+ and CD8+ T cell responses, which usually
have extremely low frequencies in cancer patients. More-
over, the use of NY-ESO-1 encoding mRNA allowed the
analysis of the entire NY-ESO-1 speciWc response without
pre-existing knowledge of epitopes and/or of restriction
elements. In addition, we show that this method is suited to
rapidly generate functional CD8 and CD4 T cell clones to a
tumour antigen in a setting independent of known epitopes
or HLA-restrictions and have identiWed a novel NY-ESO-1
epitope restricted to HLA-B*4901.
Materials and methods
Materials
Peripheral blood samples were obtained from patients and
healthy donor buVy coats (Swiss blood centre, Zurich,
Switzerland) after written informed consent. Standard
molecular methods were used to establish the HLA types of
patients. Mononuclear cells were obtained as described
[17]. Melanoma cell lines were obtained from the ESTDAB
repository [18] (www.ebi.ac.uk/ipd/estdab/) and cultured as
recommended, HLA data is available from the database.
Patients ZH-183 and ZH-493 had resected non-small cell
lung carcinoma, Stage IB and IIB, respectively. PBMC was
obtained post-resection at the time points indicated in the
results. Patient ZH-183 had the following HLA haplotype:
HLA-A*0201/6802, B*4901/5301, C*04/07. DRB1*0102/
1104, DP*0402/1701, DQ*0301/0501. Patient ZH-493:
HLA-A*0201, B*2705/3501, C*01/04.
Patient NW29 and NW1672 had stage IV and stage III
melanomas, respectively. Both patients were treated at
Krankenhaus Nordwest, Germany as previously described
[7].
In vitro stimulation of Ag-speciWc CD4/8 T cells 
with synthetic peptides
CD8 and CD4 T cells were puriWed serially from PBMC
using positive selection with MACS technology (Miltenyi
Biotech, German) according to the manufacturers instruc-
tions. T cells were stimulated in vitro with the T-cell
depleted fraction of the PBMC (APC-fraction) pulsed with
1 ug/ml of the indicated synthetic peptide as previously
described [17, 19]; except 800 IU/ml rhGM-CSF and
500 IU/ml rhIL-4 (Both R&D systems) were added at the
time of co-culture. Cultures were maintained in 25 IU/ml
rhIL-2 (R&D systems). The cytokines GM-CSF and IL-4
were added to drive diVerentiation of monocytes into pro-
fessional APC. Forty-eight hours following the addition of123
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lated CD14 and up regulated HLA-DR, CD80, CD86 and
CD83; markers for matured professional APC. In addition
we have demonstrated that the addition of these cytokines
to peptide stimulations signiWcantly increases the frequency
of peptide-speciWc CD8 T cells following in vitro stimula-
tion (N. Nuber et al., manuscript in preparation). Sets of
NY-ESO-1 overlapping 20-mer and 13-mer peptides were
generously provided by E. Jaeger, Frankfurt, Germany, and
W. Chen and I. Davis, Ludwig Institute for Cancer
Research, Victoria, Australia (Chiron Mimotopes, Victoria,
Australia), respectively.
In vitro stimulation of Ag-speciWc CD4/8 T cells 
with mRNA transduced APC
The full length NY-ESO-1 sequence was cloned in house
as previously described [20] and mRNA was produced
by CureVac GmBH (Tübingen, Germany) [21]. InXuenza
matrix protein- and green Xuorescent protein (GFP)-coding
mRNA was purchased commercially from CureVac
GmBH. The modiWed Sec-NY-ESO-1 mRNA, encoding
the natural NY-ESO-1 protein sequence, was produced
from a synthetic codon-optimised gene, commercially pro-
duced by BlueHeron Biotechnology (Bothell, WA, USA).
It was constructed as described by Kreiter et al., introduc-
ing an N-terminal signal peptide and C-terminal HLA Class
I transmembrane and cytoplasmic domain [16]. mRNA was
in vitro transcribed using the mMessage mMachine T7
(Ambion Inc.). Cells to be transduced (1–10 £ 106 cells),
as indicated in the results, were washed once and resuspend
in either 100 or 200 l cold Optimem (Invitrogen Life
Technologies) and electroporation was to be performed in a
2 or 4-mm cuvette, respectively. Cuvettes (BTX) were
cooled on ice. Cells were electroporated at the indicated
voltage and time, using a BTX 830 square wave electropo-
rator (BTX) and returned on ice. Cells were then transferred
to 1 ml prewarmed T cell medium and cultured for 18 h (or
as indicated) in sterile 5 ml polystyrene FACS tubes (BD
Falcon). Due to variation in the published protocols for
electroporation of human APCs, the conditions were opti-
mised individually for each APC type in this manuscript.
For stimulation of CD4/8 T cells, the T-cell depleted
PBMC (APC fraction) was transduced with 50 g/ml anti-
gen encoding mRNA or at the conditions described in the
results, and treated as above. Transduced APC were incu-
bated overnight (>18 h) in T cell medium plus 800IU/ml
rhGM-CSF and 500IU/ml rhIL-4 in 5 ml Polystyrene tubes
(BD Falcon), followed by irradiation at 30 Gy. T cells and
APC were co cultured at a 1:1 ratio (typically 4 £ 105 of
each) in Xat-bottom 96-well plates as described above for
synthetic peptides. For puriWcation of CD45RA+ T cells,
CD8 T cells were Wrst puriWed by positive isolation, with
DETACHaBEAD technology (Dynal, Invitrogen life sci-
ences), and subsequently with CD45RA positive selection
(Miltenyi Biotech, Germany), both according to the manu-
factures instructions. For in vitro stimulation of individual
eVector/memory T cell subsets CD8 T cells were Wrst iso-
lated with magnetic beads followed by staining with mouse
anti-human CD45RA-FITC, CD8-PE and CCR7-APC (all
BD Biosciences) and sorted as indicated with a BD
FACSAria (Flow Cytometry Laboratory, University &
ETH Zurich).
For generation of CD4+ T-APC, >1 £ 106 puriWed
CD4+ T cells were cultured in T cell media with 2 g/ml
PHA (HA16, Remel Inc. USA) and 25 IU/ml rhIL-2 and
maintained in culture for 7–10 days prior to use as targets.
Flow cytometry immunoXuorescence analysis, 
multimer-guided cloning and TCR-V analysis
PE-labelled HLA-A2/peptide multimers were synthesised
around NY-ESO-1157–165 (SLLMWITQC) or Flu-M158–66
(GILGFVFTL) and enriched CD8 T cells were stained with
the appropriate PE-labelled multimers and mAbs as
described previously [17]. Cells were immediately acquired
on a FACSCalibur, analysis was performed with FlowJo
v.7 (Tree Star Inc, USA). mAbs were from BD Biosci-
ences. Tetramer positive cells were isolated by single-cell,
multimer-guided Xow cytometry using a FACSAria (BD
Biosciences) and further cloned as described previously
[17]. TCR-V analysis of clones was performed using
the IOTest Beta Mark TCRV repertoire kit (Beckman
Coulter).
Sorting of monoclonal T cells using mRNA-transduced
targets and IFN- secretion assay
Established CD8 and CD4 T cell lines were rechallenged
with mRNA-transduced T-APC; labelled with CFSE and
cultured for >18 h in T cell medium. T cell lines and targets
were cultured at a 1:2 ratio for 4 h before performing
the IFN- secretion assay (Miltenyl Biotech, Germany),
according to the manufactures instructions. Single cells
were sorted into 96-well format plates and expanded as
described previously [17].
Intracellular IFN- analysis, IFN- ELISpot and chromium 
release assays
Recognition of target cells by T cells was tested using intra-
cellular IFN- staining as described previously [22]. A spe-
ciWc response is deemed as greater than twofold the
frequency seen with the control APC. For MHC blocking
experiments, 20 g/ml of antibody was added to the target
cells for 30 min prior to co-culture. Clones LB3.1 (HLA-DR),123
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employed. When T-APC were used as targets, they were
Wrst labelled with 1 M CFSE (Molecular probes) for
gating out. T-APC pulsed with 13–20mer NY-ESO-1
peptide(s), was performed overnight in serum-containing
media to allow for exogenous degradation and loading. Sat-
urating concentration of 25 g/ml for individual or peptide
pools, washed and co-cultured. A mock transfection of T-
APC was performed replacing mRNA with water. IFN-
ELISpot assays were performed as described previously
[23]. Lytic activity of clones was measured against peptide-
pulsed T2 cells (HLA-A2+, TAP¡/¡), EBV-transformed
B-LCL cells, and melanoma cell lines at the indicated E:T
ratios in the presence or absence of peptide in 4-h chro-
mium release cytotoxicity assays [17].
Intracellular protein expression analysis
Staining of intracellular protein was performed as described
above for IFN- with the following modiWcations. At the
time points indicated, transfected cells were Wxed with BD
CytoWx/Cytoperm Kit (BD Biosciences). Cells were
labelled with a 1:500 dilution of the mouse anti-human NY-
ESO-1 mAb (Clone E978, Zymed Laboratories Inc., CA,
USA) and a 1:250 dilution APC-labelled goat anti-mouse
IgG (BD Biosciences) using the BD CytoWx/Cytoperm Kit.
Results
Optimisation of mRNA transfection eYciency
Two diVerent APC fractions were used for mRNA transfec-
tion. For in vitro stimulation of eVector T cells, CD4/CD8-
depleted PBMC were employed. For short-term functional
T cell assays, PHA-stimulated CD4 T cell blasts (T-APC)
[24] were transfected with mRNA and used as targets. To
establish optimal conditions for protein expression follow-
ing electroporation with mRNA, the reporter molecule
enhanced green Xuorescent protein (eGFP) was employed.
Electroporation conditions were optimised for time and
voltage, with a Wxed concentration of mRNA at 50 g/ml.
For T-APC, 750 V/cm and a pulse time of 10 ms resulted in
a transfection eYciency of approximately 50% (35–65%,
n = 5), observed 18 h after electroporation. Protein could be
rapidly detected within 1 h following transfection and
peaked around 16–18 h (data not shown). Controls for auto-
Xuorescence in the FL1 (eGFP) channel were performed on
the NY-ESO-1 mRNA transfected cells (below) and was
below 0.5%. Viability 24 h post transfection was greater
than 70%, based upon forward scatter/side scatter FACS
plots (data not shown). In CD4/CD8-depleted PBMC,
detectable eGFP expression following transfection was
very low, approximately 0.5–1% in both the lymphocyte
and monocyte populations after 24 h (data not shown) and
is consistent with that reported by Teufel et al. [15]. Intra-
cellular staining for NY-ESO-1 was performed on T-APC
and T-cell depleted PBMC following transfection with NY-
ESO-1 encoding mRNA. Intracellular NY-ESO-1 protein
could only be detected in approximately 10% (8–15%,
n = 5) of T-APC after 24 h (Fig. 1a). Background staining
of the eGFP mRNA-transfected control T-APC was below
0.5% (data not shown). No signiWcant expression of NY-
ESO-1 was detected in the T-cell depleted PBMC (data not
shown). Transfection of the T2 cell line was used as a con-
trol, where approximately 90% of viable cells express NY-
ESO-1 protein 24 h after transfection (Fig. 1b). However,
based upon the widely accepted DRiP hypothesis [25]—
namely that MHC peptides may be derived from mistrans-
lated or misfolded proteins—an absence of abundant stable
protein does not negate MHC peptide presentation. Thus
the T-cell depleted PBMC (APC) were transduced with a
viral antigen to optimise and establish the in vitro stimula-
tion of antigen-speciWc T cells; hence optimisation was
based on presentation and recognition of MHC-peptide.
The CD4/CD8 depleted PBMC (APC-enriched fraction)
was transduced with InXuenza matrix protein M1 (Flu M1)-
encoding mRNA (750 V/cm, 10 ms) or pulsed with the
HLA-A2-restricted peptide Flu-M158–66. Autologous CD8
T cells were added to the APC 18 h later and maintained in
culture for 10 days. Following this one in vitro stimulation
with either peptide or mRNA, using HLA-peptide multi-
mers we observed a frequency of HLA-A2.1/Flu-M158–66-
positive cells of 21 and 18%, respectively (Fig. 1c). To
determine the impact of mRNA concentration on the per-
centage of speciWc CD8 T cells, a titration experiment was
performed. In the two HLA-A2 positive healthy donors
shown, increasing Flu-M1 mRNA concentrations resulted
in an increase in the frequency of Flu-M158–66 speciWc CD8
T cells, with a maximum frequency observed at 50 g/ml
(Fig. 1d). For all further experiments a concentration of
50 g/ml is utilised.
Cancer/testis antigen, NY-ESO-1, encoding mRNA
Although viral antigens such as CMV pp65 are useful tools
for establishing in vitro systems, often the transfer of meth-
odologies from viral antigens to tumour antigens is prob-
lematic, in particular due to the diVerences in precursor
frequencies between T cells speciWc for these two groups of
antigens. Therefore to determine if the in vitro use of anti-
gen-encoding mRNA is feasible for investigating TAA-
speciWc T cells, NY-ESO-1 was chosen as a representative
tumour antigen. Based on the observed correlation between
cellular and humoral immune responses [26, 27], cancer
patients with a detectable anti-NY-ESO-1 IgG titre were123
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tion of GM-CSF and IL-4 to in vitro stimulations was
included as these cytokines will drive diVerentiation of pro-
fessional APC in PBMC, as seen by down regulation of
CD14 and up-regulation of CD80, CD86 and HLA-DR.
Moreover, we also observe a signiWcant increase in the fre-
quency and function of speciWc T cells stimulated in vitro
with synthetic peptides using this cytokine supplementation
approach (N. Nuber et al., manuscript in preparation). In
patient ZH-183, one in vitro stimulation with NY-ESO-1
mRNA-transduced CD4/CD8-depleted PBMC (in the pres-
ence of GM-CSF and IL-4), a frequency of 0.4% A2/NY-
ESO-1157–165-positive cells was detected with Xuorescent
multimers (Fig. 2a). In contrast, in the absence of GM-CSF
and IL-4, NY-ESO-1157–165-speciWc CD8 T cells were not
detectable (data representative of more than one experi-
ment).
To conWrm the speciWcity monoclonal anti-NY-ESO-
1157–165 speciWc CD8 T cells were obtained by Xow cyto-
metric sorting of multimer labelled cells (Fig. 2b). The
avidity of the clones was assessed using T2 cells, pulsed
with increasing peptide concentrations in a chromium
release assay. As a representative example, clone ZP-311
1G3 exhibits an IC50 of 10¡10 M suggesting an intermedi-
ate to high avidity (Fig. 2c). Moreover, this clone demon-
strated functional killing of an allogeneic tumour cell line
co expressing HLA-A2.1 and NY-ESO-1 (SK-MEL-37)
whereas no killing was observed of the HLA mismatched
(NW-MEL-634) or NY-ESO-1-negative control cell lines
(NW-MEL-1715) (Fig. 2d).
Fig. 1 Optimisation of mRNA transfection eYciency. a T-APC were
transfected with 50 g/ml of mRNA encoding eGFP (left) or NY-ESO-
1 (right) and samples Wxed at the time points indicated. Intracellular
(IC) NY-ESO-1 was labelled after permeabilization, and expression of
both proteins analysed in viable cells by Xow cytometry. Viability 24 h
post electroporation was >70% based on FACS analysis. b IC NY-
ESO-1 expression in T2 cells was analysed at the time points indicated
following transfection. c PBMC from an HLA-2 positive healthy donor
were transduced with 25 g/ml Flu-M1 mRNA (left) or pulsed with
1 ug/ml of the Flu M1 peptide p58–66 (right), both in the presence of
rGM-CSF and rIL-4. Dot plots demonstrate the percentage of HLA-
A2/Flu M158–66-positive CD8+ T cells labelled with multimers after 10
days of culture. d Quantity of Flu-M1 mRNA used to transfect PBMC
from HLA-A2 positive healthy donors (H.D. 1 and 2) was titrated and
the percentage of HLA-A2/Flu M158–66-positive CD8+ T cells after 10
days determined with Xuorescent multimers123
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to NY-ESO-1 in patients with NSCLC
To determine the breadth of the speciWc T cell response
expanded by stimulation with NY-ESO-1 encoding mRNA,
two NSCLC patients were analysed. CD8/CD4-depleted
PBMC were transduced with NY-ESO-1 mRNA and used
as APC for one round of in vitro stimulation with the autol-
ogous CD8 T cells. To assess the frequency of speciWc CD8
T cells following stimulation, T-APC were used as autolo-
gous targets in an intracellular IFN- assay. For this assay
T-APC were either pulsed with the NY-ESO-1157–165 pep-
tide, mock-transduced or transduced with NY-ESO-1
mRNA (Fig. 3a). Patient ZH-183 had detectable frequen-
cies of NY-ESO-1157–165 speciWc cells at both time points.
A frequency of 0.13% speciWc CD8 T cells was observed
with NY-ESO-1157–165 peptide-pulsed T-APC targets,
whereas a threefold higher frequency of 0.41% speciWc
CD8 T cells was observed when T-APC targets transfected
with mRNA were used. HLA-A2.1 homozygous patient
ZH-493 did not have any detectable NY-ESO-1157–165 spe-
ciWc cells, however speciWc CD8 T cells were detected with
mRNA transduced APC; frequency 0.26% with CD8 T
cells from time point October 2005 (Fig. 3a).
To exclude that naïve cells are primed de novo, CD8 T
cells from ZH-183 were separated into CD45RA positive
and depleted fractions and stimulated in vitro. Thereafter,
analysis with control or NY-ESO-1 peptide-pulsed APC by
intracellular IFN- staining demonstrates that the NY-ESO-
1 speciWc cells are exclusively found within the antigen
experienced T cell repertoire of stimulated patients; where
0.42% of speciWc cells were seen only in the CD45RA
depleted stimulation (Fig. 3b). Recognition of the control
APC was below 0.05% for both the CD45RA positive and
depleted fractions (result shown for the depleted fraction).
Purity of the CD8/CD45RA positive fraction exhibited
Fig. 2 Analysis of NY-EYO-
1157–165 speciWc CD8+ T cells in 
patient ZH-183 following one 
round of in vitro stimulation 
with NY-ESO-1 mRNA. a The 
CD8-depleted fraction of PBMC 
from HLA-A*0201-positive 
patient ZH-183 (Z-P-311) were 
transduced with NY-ESO-1 mR-
NA, co-cultured with autologous 
CD8+ T cells in the presence 
(right) or absence (left) of rGM-
CSF and rIL-4. Cells were 
maintained in culture for 10 days 
with rIL-2 and analysed using 
Xuorescent HLA-A2/NY-ESO-
1157–165 multimers. b HLA-A2/
NY-ESO157–165 positive CD8+ 
T cell clones were generated by 
FACS-assisted single-cell 
sorting of HLA-multimer 
labelled cells. c Functional 
avidity of clones was determined 
by peptide-titration experiments 
showing killing of peptide-
loaded TAP-deWcient T2 cells 
using a standard chromium 
release assay. d SpeciWc killing 
of NY-ESO-1 expressing 
tumour cells was demonstrated 
in a standard chromium release 
assay with tumour cell lines. 
Eso, NY-ESO-1123
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with magnetic beads from a healthy HLA-A2+ donor (HD-
692) and a third HLA-A2+ cancer patient with detectable
anti-NY-ESO-1 serology (ZH-107) were FACS sorted
based upon CD45RA and CCR7 expression [28] (Fig. 3c).
Unsorted CD8 T cells and the four sorted populations of
CD8 T cells from HD-962 and ZH-107 were stimulated in
vitro with the autologous APC-fraction transfected with
mRNA encoding the Flu-M1 and NY-ESO-1 antigen,
respectively. After 9 days of co-culture the cultures were
labelled with anti-CD8 mAb and the HLA-A2.1 multimers
containing the relevant peptides (previously described).
Fig. 3 Analysis of naturally occurring CD8+ responses to NY-ESO-1
in patients with NSCLC. a CD8 T cells from two non-small cell lung
cancer (NSCLC) patients were expanded in vitro with mRNA encod-
ing NY-ESO-1 at two time points post surgery, and whilst disease free.
The frequency of NY-ESO-1 speciWc CD8+ T cells was determined us-
ing intracellular IFN-g analysis upon challenge with T-APC; either
pulsed with the HLA-A2-restriced pp157–165 epitope or transfected
with NY-ESO-1 mRNA. b Stimulation of naïve and antigen experi-
enced CD8+ T cells with NY-ESO-1 mRNA. PuriWed CD8+ T cells
from ZH-183 were further fractionated into CD45RA-enriched (mid-
dle) or -depleted populations (right) and subjected to one in vitro stim-
ulation with NY-ESO-1 transduced autologous APC. Dot plots
indicate intracellular IFN- production in APC-negative, CD3+CD8+
positive T cells following rechallenge with autologous T-APC pulsed
with an NY-ESO-1 peptide or control T-APC (left). c Stimulation of
sorted CD45RA/CCR7+/- CD8+ T cells with mRNA. PuriWed CD8+
T cells from HD-962 and ZH-107 were FACS sorted based upon
CD45RA and CCR7 expression (Left; upper and lower panels, respec-
tively) and each population was stimulated in vitro with autologous
APC transfected with Flu-M1 or NY-ESO-1 mRNA, respectively. On
day 9 speciWc cells were assessed with Xuorescent HLA-A2.1 multi-
mers containing the Flu-M158–66 (upper panels) and NY-ESO-1157–165
(lower panels) epitopes123
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found in the unsorted CD8 stimulation (24%) and mainly in
the CD45RA¡/CCR7¡ eVector memory (28%) and the
CD45RA+/CCR7¡terminally diVerentiated eVector (12%)
stimulations. A smaller population was also observed in the
CD45RA+/CCR7+ naïve stimulation (3%). CD45RA¡/
CCR7+ central memory T cells did not expand after in vitro
stimulation, also observed with ZH-107. With patient
ZH-107, HLA-A2.1/NY-ESO-1157–165-positive cells were
found only within the unsorted CD8 stimulation (0.24%)
and the CD45RA¡/CCR7¡ eVector memory (0.07%) stim-
ulations (Fig. 3c).
These data indicate that for NY-ESO-1 only the pool of
memory cells have been expanded and naïve cells are not
primed. Due to insuYcient material this assay could not be
performed in patient ZH-493. Moreover, NY-ESO-1 spe-
ciWc CD8 T cells were not detected in >5 healthy donors,
which would contain only a speciWc naïve population, after
one in vitro stimulation (data not shown). A small percent-
age of naïve cells speciWc for Flu-M1 were expanded. It is
diYcult to exclude that these cells expanded from
CD45RA+/CCR7¡ CD8 T cells contaminating the naïve
pool after sorting. Phenotypical analysis of the multimer
positive cells indicates that the stimulated naïve pool still
contained a population of speciWc cells with a CD45RA+/
CCR7+ naïve phenotype, and thus had not been primed in
vitro (data not shown).
In order to conWrm antigen speciWcity and to assess the
clonality of the response, NY-ESO-1 speciWc CD8 T cells
from ZH-183 and ZH-493 secreting IFN- (following re-
challenge with mRNA-transduced autologous APC) were
single cell sorted. SpeciWcity was conWrmed using an IFN-
ELISpot assay (data not shown). The TCR V repertoire of
speciWc clones was analysed. Figure 4a conWrms that both
patients mounted a polyclonal response as demonstrated by
multiple TCR V usages of the speciWc clones.
To ascertain the HLA-restriction of the speciWc clones
and to demonstrate functionality, a panel of HLA-matched
allogeneic melanoma cell lines that were either NY-ESO-1
expressing or non-expressing were selected from the EST-
DAB cell bank [18] (data available at: www.ebi.ac.uk/ipd/
estdab/). A panel of cell lines covering all the relevant
MHC class I molecules for each patient were used as tar-
gets in a standard chromium release assay. Examples for
three clones, two from patient ZH-183 and one from ZH-
493 are shown (Fig. 4b). Clone ZH183 2D11 that is spe-
ciWc for the HLA-A2.1/NY-ESO-1157–165 epitope demon-
strated speciWc killing of ESTDAB-27, an NY-ESO-1,
HLA-A2.1 positive cell line. Clone ZH183 2G5 speciW-
cally kills ESTDAB-133, an NY-ESO-1 positive line
matched on HLA-B*49. Whereas, the HLA-B*49 positive,
NY-ESO-1 negative cell line ESTDAB-29 was not killed.
Clone ZH493 3F10 demonstrated speciWc killing of the
NY-ESO-1 positive cell line ESTDAB-11, matched on
HLA-C*0401.
To deWne the minimal sequence of the undeWned B*49-
restricted epitope, autologous APC were pulsed overnight
with overlapping 20-mer peptides spanning the whole pro-
tein sequence. The HLA-B*49-restricted clone ZH183 2G5
speciWcally recognises peptide p119–143 in an ELISpot
assay (Fig. 4c). Similar results were seen with HLA-B*49-
restricted clone ZH183 3B3 (data not shown). HLA-Cw04-
restricted clone ZH493 3F10 demonstrated speciWc recog-
nition of peptide p91-110 (data not shown). To deWne the
minimal HLA-B*49 restriction element, clone ZH183 2G5
was tested with overlapping 13-mers covering NY-ESO-1
positions 119–143, where speciWc recognition of peptide
p124–136 is observed (data not shown). The use of 12-, to
8-mers covering this sequence demonstrate that the mini-
mal epitope recognised was pp124–135 (KEFTVSGNILTI)
(Fig. 4d). This peptide contains the known HLA-B*49
MHC anchor residues; glutamic acid in position 2 and a
valine, leucine or isoleucine in position 9 (www.syfpeithi.
de).
Analysis of naturally occurring CD4+ T cell responses 
to NY-ESO-1
To determine if NY-ESO-1-speciWc CD4+ T cell responses
could be detected in patients, puriWed CD4+ cells were
stimulated in vitro as described. For this purpose, a modi-
Wed mRNA coding for an NY-ESO-1 antigen having a sig-
nal sequence to direct the translated protein to the secretory
pathway (Sec-NY-ESO-1 mRNA) was used. This modiWca-
tion was recently described by others and shown to enhance
MHC class II presentation [16]. Here, we compared the
wild type (WT-NY-ESO-1) mRNA with the Sec-NY-ESO-
1 to stimulate a CD4+ response in patient ZH-183. Again,
one in vitro stimulation with mRNA-electroporated APC
fraction was utilised and assessment of IFN- performed
using T-APC targets pulsed with the pool of 20-mer pep-
tides spanning the whole sequence. Peptide-pulsed T-APC
were employed to exclude CD4+ cells that may have been
speciWc for potential novel epitopes in the fusion region
between the antigen and signal sequences. In this example
we see a CD4+ T cell frequency of 0.59 and 1.83% for the
WT- and Sec-NY-ESO-1 mRNA, respectively (Fig. 5a).
In a stimulation of CD4 T cells from ZH-183, from a
second time point, read-out was performed with T-APC
transduced with Sec-NY-ESO-1 mRNA, a pool of the over-
lapping peptides, or each of the peptides individually
(Fig. 5b). In this analysis CD4 T cells speciWc for the
peptides pp41–60 (0.27%), pp51–70 (7.17%), pp61–80
(0.77%), pp91–110 (0.14%), pp119–143 (0.35%), pp151–
170 (3.35%) and pp161–180 (3.49%) were detected, where
background with the control APC was <0.05%. NY-ESO-1123
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means of single cell sorting of IFN- producing cells. Spe-
ciWc clones were assessed by IFN- ELISpot with pooled or
individual overlapping 20-mer peptides to determine the
breadth of the response. Of 85 speciWc clones 70 recognised
the peptide pp51–70, 1 clone pp91–110, and 14 clones
recognised both pp151–170 and pp161–180 (data not
shown). Recently a novel HLA-DQ*0301 epitope con-
tained within p51–70 was described [29]; an HLA allele
expressed by patient ZH-183. Clones were tested for recog-
nition with either an autologous B-LCL line or an alloge-
neic B-LCL matched or mismatched on HLA-DQ*0301,
pulsed with peptide NY-ESO-1 pp51–70, in an IFN-
assay. Recognition of only the autologous and HLA-
Fig. 4 Analysis of NY-ESO-1 
speciWc CD8+ T cell clones 
obtained following mRNA stim-
ulation of patients ZH-183 and 
ZH-493. CD8+ T cells from both 
patients were stimulated with 
autologous APC transduced with 
NY-ESO-1 mRNA in vitro, and 
after 10 days rechallenged with 
mRNA-transduced autologous 
T-APC. IFN- producing cells 
were single cell sorted, clones 
expanded and speciWcity con-
Wrmed. a TCR-V usage of the 
speciWc clones was analysed 
using a commercial serological 
method. V n/a—not available 
with method employed. b To 
address functionality and HLA-
restriction, clones were used in a 
standard chromium release kill-
ing assay with allogeneic EST-
DAB tumour cell lines. A panel 
of cell lines matched for each of 
the class I allelic variants rele-
vant for each patient, expressing 
or non-expressing NY-ESO-1 
were selected. EVector: Target 
ratios are indicated, in addition 
to the resultant HLA-restriction. 
c A set of overlapping 20-mer 
NY-ESO-1 peptides were used 
to deWne the region recognised 
by clone ZH183 2G5 in an IFN-
 ELISpot with autologous APC. 
d Subsequently 13-mers to 8-
mers were employed to deWne 
the minimal epitope using 
autologous T-APC and an intra-
cellular IFN analysis to deWne 
speciWcity. All polypeptides 
were Wrst pulsed on APC 
for >18 h123
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indicate restriction to this allele (Fig. 5c). Blocking
experiments conWrmed HLA-DQ restriction (Fig. 5c).
Interestingly, CD4 T cell clone 2–46 demonstrated concur-
rent recognition of two NY-ESO-1 peptides: 151–170 and
161–181 (Fig. 5d), which are 20-mer peptides overlapping
by ten amino acids. Blocking experiments indicate that
both peptides are recognised in the context of HLA-DP
(Fig. 5d).
Analysis of NY-ESO-1 vaccinina/fowlpox vaccinated 
patients using mRNA encoding NY-ESO-1
We extended our analysis to two patients (NW29 and
NW1672) that had been enrolled in an NY-ESO-1 vaccine
program [7]. CD4 and CD8 T cells were stimulated once in
vitro with mRNA encoding NY-ESO-1 (WT- for CD8 and
Sec-NY-ESO-1 mRNA for CD4 T cells). CD4+ T cells
were also used to generate T-APC targets. PBMC were
obtained at days 29, 43 and 113 of the trial for NW29, and
days 260 and 365 for NW1672. Intracellular IFN- analysis
was performed using autologous T-APC pulsed with the
20-mer peptides, mock- or WT-NY-ESO-1 mRNA-trans-
duced.
NW29 demonstrated a high frequency of NY-ESO-1
speciWc CD8 T cells at all three time points after analysis
with mRNA-transduced T-APC; 3.7, 5.1 and 2.6% for days
29, 43 and 113, respectively (Fig. 6a). These frequencies
are approximately tenfold higher than those observed in
patients with a naturally arising response. This patient was
tested for recognition of peptides p81–100, p91–110 and
p119–143, to which a response was reported by Jager et al.
[7]. For peptide 81–100, frequencies of approximately 8%
were observed at all time points. For peptide 91–110, fre-
quencies of 2.4, 7.4 and 1.9% for days 29, 43 and 113,
respectively. For peptide 119–143; 2.7, 3.3 and 0.6% for
days 29, 43 and 113, respectively (Fig. 6a).
For patient NW1672 analysis of CD8 T cells at the later
time points days 260 and 365 also demonstrated a strong
response to autologous APC transduced with NY-ESO-1
mRNA following one in vitro stimulation; 4.6 and 3.5% of
gated CD3/CD8 positive cells, respectively. To compare
Fig. 5 Analysis of NY-ESO-1 speciWc CD4+ T cells obtained follow-
ing mRNA stimulation of patient ZH-183. a CD4+ T cells were stim-
ulated with autologous APC transduced with either the wild type (WT)
(above), or modiWed (sec) NY-ESO-1 mRNA (below). After 20 days
NY-ESO-1 speciWcity of gated APC-negative, CD3-positive, CD4-
positive cells was assessed with an intracellular IFN- assay, employ-
ing autologous T-APC pulsed with a pool of 20-mer overlapping
peptides spanning the full protein length (right), or control un-pulsed
T-APC (left). b Sec-ESO-mRNA stimulated CD4+ T cells from ZH-
183 were challenged with T-APC transduced with Sec-NY-ESO-1
mRNA, pulsed with the 20-mer peptide pool, or each peptide individ-
ually, and intracellular IFN- determined by FACS analysis. c HLA
restriction of clone 1–8 recognising peptide p51–70 was conWrmed by
analysis of IFN- following challenge with HLA-DQ*0301 matched/
mis-matched B-LCL (Exp. 2) and blocking of MHC/TCR interaction
with MHC-class II mAbs (Exp. 1). d Clone 2–46 was challenged with
autologous B-LCL pulsed with peptides p151–170 or p161–180 and
blocking or recognition performed with MHC-class II mAbs123
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20-mer peptides spanning the protein sequence, CD8 T
cells from patient NW1672—following one round of in
vitro stimulation—were challenged with T-APC pulsed
with the peptide pool. Lower frequencies were observed
with T-APC pulsed with the pool of peptides than observed
for the mRNA-transfected APC; CD8 T cell frequencies
from time points days 260 and 365 with the peptide-pulsed
APC were; 3.6 and 2.6%, respectively (Fig. 6b).
For analysis of CD4+ responses in patient NW29, the
modiWed Sec-NY-ESO-1 mRNA was employed for in vitro
stimulation. Assessment of speciWc responses was made
with T-APC pulsed with pooled or individual 20-mer pep-
tides. NY-ESO-1 speciWc CD4+ T cells recognising the
peptide pool were detectable at all three time points; 2.9,
1.9 and 1.0% for days 29, 43 and 113, respectively
(Fig. 6c). Responses above the background seen with con-
trol APC (<0.18%) were observed for days 29, 43 and 113
(respectively) for peptides p81–100 (0.6, 0.6 and 0.3),
p119–143 (1.0, 0.9 and 0.4%) and p139–160 (2.1, 1.9 and
1.2%). Weak but clear responses were seen towards peptide
p111–130 on days 29 and 43 (0.4 and 0.3%) (Fig. 6c). For
patient NW1672, low frequencies of CD4+ cells were
observed for a Wnite number of the 20-mer peptides.
Responses to peptides p119–143 (0.19%), p139–160
(0.17%) and p161–180 (0.34%) can be observed on day
265, whereas on day 365 responses to p139–160 (0.61%)
and p161–180 (0.48%) were observed (background 0.1%)
(data not shown).
Discussion
Precise assessment of spontaneous and vaccine-induced
anti-tumour immunity in cancer patients is critical for
understanding the therapeutic potential of cellular immune
Fig. 6 Analysis of NY-ESO-1 
speciWc CD8+ and CD4+ T cell 
responses in patients following 
vaccination with vaccinia/fowl-
pox NY-ESO-1. PBMC were 
obtained from patients NW29 
and NW1672 following initia-
tion of vaccination, at the time 
points indicated, and analysed 
for CD8+ and CD4+ T cell 
responses using wild type and 
modiWed (Sec) NY-ESO-1 mR-
NA, respectively. Following in 
vitro stimulation with mRNA, 
T cells were rechallenged with 
autologous T-APC and intracel-
lular IFN- assessed on gated 
APC-negative, CD3-positive, 
CD4/8-positive. CD8+ from 
NW29 (a) and NW1672 (b) 
were assessed for recognition of 
mRNA-transduced, peptide-
pool pulsed or individual 20-mer 
peptide pulsed T-APC, at the 
time points indicated. CD4+ T 
cells from NW29 (c) were 
assessed for recognition of pep-
tide-pool pulsed or individual 
20-mer peptide pulsed T-APC, 
at the time points indicated. 
D day, PP amino acid position. 
Mock control transfection with 
water123
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encoding for the therapeutically relevant antigen, NY-ESO-
1, we provide evidence of a highly eYcient approach to
address the breadth and the magnitude of CD8 and CD4 T
cell responses in cancer patients. Importantly, detection is
not limited to a Wnite set of epitopes and HLA restrictions.
Moreover, we document the sensitive induction of NY-
ESO-1 speciWc T cell responses in vitro that allowed the
successful ampliWcation of a low frequency of antigen-
experienced precursors otherwise undetectable directly
ex vivo.
Due to the sensitivity limits of existing immunomonitor-
ing technologies and the low precursor frequencies of
tumour antigen-speciWc T cells in peripheral blood—even
following vaccination—in vitro stimulation still remains a
necessity in most cases. Although some studies have dem-
onstrated ex vivo detection of TAA-speciWc peripheral T
cells [30–32] these are not frequent observations. It has
been suggested that the functional capacity of speciWc T
cells may be considered more relevant than the overall fre-
quency of cells present [33]. Clearly in vitro stimulation
ablates the capacity to determine functionality as it existed
in vivo. In light of immune modulation being mediated
locally within the tumour [22, 34], functional analysis of
peripheral blood T cells directly ex vivo also does not pro-
vide an indication of how eVective a therapy may have been
at eliciting functional T cells at the tumour site [35]. Where
immune monitoring does play a critical role is to address
the induction and the breadth of an immune response result-
ing from a given therapy, especially relevant for developing
vaccines comprising whole antigen as opposed to single
epitopes, and to address the induction of both CD8 and
CD4 T cells—including induction of memory—to enable
correlations with clinical outcomes.
Recently, a number of groups have applied in vitro stim-
ulation with mRNA to address immune responses [15, 36,
37]. Few studies have expanded their analysis beyond that
of proof of principle investigations involving viral antigens
[15, 16, 38], where comparatively large frequencies of high
avidity T cells exist within the periphery of most healthy
donors, and it remains to be addressed if their methodology
would allow for the detection of TAA-speciWc T cells. One
study did, however, presented preliminary data suggesting
the expansion and detection of CD4 T cells recognising
NY-ESO-1 in cancer patients [38]. Here we were able to
reproducibly stimulate NY-ESO-1 speciWc CD8 T cells in
patients with a low precursor frequency of speciWc cells,
below ex vivo detectable limits, present as a result of natu-
rally occurring immunity to their tumour or following NY-
ESO-1 vaccination. In two HLA-A*0201 positive patients
with spontaneous humoral immunity, ex vivo frequencies
of cells speciWc for the HLA-A2.1/157-165 epitope could
not be detected. We demonstrate that following one in vitro
stimulation, detectable frequencies of speciWc T cells could
be expanded from the PBMC of patient ZH-183, where fur-
ther cloning enabled attainment of speciWc, functional
clones. A novel HLA B*4901-restricted epitope from NY-
ESO-1, position 124–135, was identiWed using these
clones. No speciWc cells were found in the HLA-A2.1
homozygous patient ZH-493 to the formerly supposed
immunodominant epitope pp157–165. Subsequent cloning
and analysis suggests that some clones in patient ZH-493
are restricted to HLA*Cw4. Utilising one round of in vitro
stimulation with a low quantity of PBMC enables a rapid
and straightforward immune monitoring strategy. We
applied the system for immunomonitoring of clinical trials
by analysing PBMC from patients enrolled on an NY-ESO-
1 vaccinina/fowlpox trial [7]. Here we demonstrated that
we were able to detect speciWc CD8 T cells recognising
three dominant C-terminal regions of NY-ESO-1 in patient
NW29 [7], and analysis of patient NW1672 demonstrated
that NY-ESO-1 speciWc T cells were still readily expand-
able in high frequencies 1 year following the Wrst vaccina-
tion. The absence of NY-ESO-1 speciWc T cells following
in vitro stimulation of healthy donors, as well as the
absence of speciWc cells in the naive fraction of two
patients CD8 T cells, demonstrates that we are only
expanding antigen-experienced cells. An important consid-
eration when using in vitro stimulation to monitor vacci-
nated patients. We were unable to detect speciWc T cells to
the tumour antigen NY-ESO-1 ex vivo (data not shown), as
shown by others for viral antigens [38], and attribute this
disparity to the large diVerence in precursor frequencies
between viral and tumour antigen-speciWc T cells.
To enhance MHC class II processing, modiWcations
aimed at targeting the translated protein to the secretory
pathway have be described [39–41]. Recently the inclusion
of an MHC class I traYcking domain, comprised of an
MHC class I signal peptide and the transmembrane/cyto-
plasmic region fused to the N- and C-terminus of the anti-
gen, respectively, was described [16]. This modiWcation
was shown to speciWcally target the encoded antigen to
diverse antigen-processing compartments and signiWcantly
enhances MHC class I and II loading [38]. Concurrently we
have constructed a modiWed NY-ESO-1 mRNA molecule
in this manner (termed Sec-NY-ESO-1 mRNA). We dem-
onstrate that in vitro stimulation with the Sec-NY-ESO-1
mRNA resulted in an increase in the frequency of NY-
ESO-1 speciWc CD4+ T cells, conWrming that this modiW-
cation enhances the stimulation of CD4+ T cells [38]. In
our study peptide pulsed targets were used to ensure recog-
nition was restricted to NY-ESO-1 epitopes and not any
potential novel epitopes derived from the fusion region
between the antigen and signal sequences. SpeciWc CD4 T
cell clones recognising an HLA-DQ*0301 restricted
epitope [29] were readily expandable from these in vitro123
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recognised peptides p151–170 and p161–180 concurrently,
suggesting the decamer motif shared between these two
overlapping peptides must be involved in binding on HLA-
DP molecules and TCR recognition in this context. Analysis
of CD4 T cell responses in the vaccinated patients NW1672
and NW29 demonstrated a polyclonal response to NY-
ESO-1 recognising a broad array of epitopes, with large fre-
quencies of cells similar to those achieved in the CD8 reper-
toire being observed for patient NW29. Unfortunately in
this retrospective analysis, due to limited material, no pre-
vaccination PBMC were available to assess for pre-existing
T cell responses in these patients and thus one can only
speculate that the higher-frequencies of NY-ESO-1 speciWc
T cells were induced as a result of the therapy. Taken
together these data indicate the applicability of in vitro stim-
ulation with antigen-encoding mRNA to monitor CD4 and
CD8 T cell responses in cancer patients.
In summary, we describe the eYcient and rapid analysis
of tumour antigen speciWc CD4 and CD8 T cells, from lim-
ited amounts of cryopreserved PBMC, by employing anti-
gen-encoding mRNA that allows the analysis of all natural
epitopes from a given antigen. By extending our analysis
beyond that of reference viral antigens to a therapeutically-
relevant tumour-TAA and analysing NY-ESO-1 vaccinated
patients, we demonstrate this system has real potential for
immune monitoring of vaccine trials. By using a single in
vitro stimulation with a sensitive readout strategy one can
ensure that the expanded cells are indeed in vivo ampliWed
antigen-experienced cells as opposed to in vitro primed
naïve cells, which may give false positive results and an
incorrect judgement of the vaccine trial. Successful immun-
omonitoring, in addition to the analysis of tumour suscepti-
bility to the immune responses (e.g. MHC/antigen loss,
immune inWltration etc.) and follow-up of clinical outcomes
are all requirements for the continued development of eVec-
tive cancer vaccines.
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